This inventor holds 4 USPTO granted patents and 6 published patent applications. Top assignees: Gilead Sciences, Inc., Ausperbio Therapeutics Inc.. Active years: 2014-2026.
Company Filing History:
Years Active: 2014-2026
Title: Guofeng Cheng: Innovator in Hepatitis C Research
Introduction
Guofeng Cheng is a notable inventor based in Foster City, CA (US). He has made significant contributions to the field of hepatitis C research, particularly through his innovative work on replicons. With a total of 4 patents, Cheng has focused on developing methods that enhance the understanding and treatment of hepatitis C virus (HCV).
Latest Patents
Cheng's latest patents include groundbreaking work on HCV genotype 6 replicons. These replicons contain adaptive mutations that enable the HCV to replicate in vitro. His research also provides methods for preparing genotype 6 replicons and utilizing them to screen antiviral agents. Additionally, he has developed HCV genotype 3 replicons, which similarly contain adaptive mutations that facilitate in vitro replication. This work includes methods for preparing genotype 3 replicons and their application in screening antiviral agents.
Career Highlights
Guofeng Cheng is currently employed at Gilead Sciences, Inc., where he continues to advance his research in hepatitis C. His work has been instrumental in providing new insights into the virus and potential treatment options.
Collaborations
Cheng collaborates with several esteemed colleagues, including William E Delaney, Iv, and Hongmei Mo. These partnerships enhance the research efforts and contribute to the development of innovative solutions in the field.
Conclusion
Guofeng Cheng's contributions to hepatitis C research through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in antiviral therapies and understanding of the virus.